Nephros, Inc. (NEPH) - Cekelan dhuwit saben saham

Nephros, Inc. (NEPH) is developing an ultrafiltration system for US clinics, integrating Legionella protection into hospital protocols. Cash per share trends demonstrate current liquidity, with the parameter stabilizing at 0.42. American medical purifier manufacturing plants ensure stability. High FDA barriers and unique membrane patents securely protect the market niche from new entrants.
Rincian analitis perusahaan Nephros, Inc.

Liquidity is critical for Nephros, Inc. (NEPH) when scaling partnerships to implement ultrafiltration systems in clinics. This metric is calculated by dividing total cash and cash equivalents by the number of shares outstanding. By analyzing the cash per share calculation, an investor assesses the real capital value per security. High values confirm financial stability but may signal low efficiency in reserve management. This metric determines the issuer's fundamental margin of safety.